Immune Network Signs Letter of Intent for CDT License.Business Editors VANCOUVER, B.C.--(BUSINESS WIRE)--Sept. 19, 2001 Immune Network Ltd. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :IMMKF IMMKF Interacting Multiple-Model Kalman Filter ) (CDNX CDNX See Canadian Venture Exchange (CDNX). :IMM IMM See: International Monetary Market .) signed a letter of intent today with Nutraceutix, Inc. (http://www.nutraceutix.com) (OTCBB:NUTX) to co-develop novel formulations for several existing gerontology drugs. According to the letter of intent, Nutraceutix will commence a development program for certain pharmaceuticals selected by Immune Network. Immune Network has elected to employ the CDT(TM) Controlled Delivery Technology as an optimum technology for drug delivery of certain specific drugs and drug combinations to be used in treating Alzheimer disease and other neurodegenerative diseases. The CDT(TM) technology was invented by Dr Reza Fassihi in the pharmaceutical laboratories of Temple University (Philadelphia) and has been licensed exclusively to Nutraceutix. Using patented CDT(TM) technology, monolithic tablets for oral administration can be designed having several advantages over conventional sustained-release tablets. Immune Network and Nutraceutix will commence the formulation development program immediately. Initial work will be carried out at Temple University in conjunction with Nutraceutix, followed by technology transfer to a development partner for scale-up and cGMP manufacturing. Nutraceutix is a leading provider of proven formulation technologies for both prescription and non-prescription healthcare products. The CDT(TM) technology is currently utilized in several marketed products. Nutraceutix will be presenting three abstracts regarding unique product formulations at the 2001 American Association of Pharmaceutical Scientists (AAPS AAPS American Association of Pharmaceutical Scientists AAPS Association of American Physicians and Surgeons AAPS Ann Arbor Public Schools AAPS American Association of Plastic Surgeons AAPS African Association of Political Science ) Annual Meeting, October 21-25, 2001 in Denver. Immune Network is a "biotech merchant developer" that acquires, adds value, and divests drug discovery projects. Immune Network's focus is Alzheimer disease and the company also has holdings and interests in a number of other projects. On behalf of the Board of Directors Allen Bain, Ph.D., CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. "Safe Harbor" Statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995: This news release contains forward looking statements that are not historical facts and are subject to risks and uncertainties which could cause actual results to differ materially from those set forth in or implied herein. These risks are described in detail in the company's Securities and Exchange Commission filings. The Canadian Venture Exchange The Canadian Venture Exchange (CDNX) is now a defunct stock exchange having been acquired by the TSX Group in 2001 and renamed the TSX Venture Exchange. History of the Canadian Venture Exchange (CDNX) has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion